On September 8, Boston Scientific fell 4.08% in pre-market trading, trading at $45.69/share, with turnover of approximately $567,600. The decline comes as the company disclosed through an SEC filing that a previously identified cybersecurity incident continues to cause global operational disruptions.

According to the filing, Boston Scientific identified the cybersecurity incident on August 25, which compromised certain information technology systems and caused network outages affecting company operations. The company activated its incident response protocols and engaged third-party cybersecurity experts to assess and contain the threat. The incident has limited access to operational systems and business applications, disrupting customer order processing and product shipment across multiple markets. The timeline for full restoration remains unknown, and the company has stated it cannot yet determine whether the incident will have a material impact on its financial results.

The cybersecurity disruption compounds existing headwinds for Boston Scientific, which in late August also faced an FDA Class I recall of certain ENROUTE Transcarotid Neuroprotection System catheters due to arterial sheath tip separation risks, and in late July lowered its full-year guidance citing weakness in its Watchman and electrophysiology portfolios.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)